Clearside Biomedical (Nasdaq:CLSD) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

CLSD Stoklara Genel Bakış

Bir biyofarmasötik şirketi olan Clearside Biomedical, Inc. tedavilerin suprakoroidal boşluk yoluyla gözün arka kısmına ulaştırılmasında devrim yaratmaya odaklanmaktadır.

Şirket hakkında

CLSD temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	1/6
Temettüler	0/6

Ödüller

Revenue is forecast to grow 65.68% per year

Earnings have grown 3.5% per year over the past 5 years

Risk Analizi

Negative shareholders equity

Has less than 1 year of cash runway

Does not have a meaningful market cap ($95M)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 daha fazla risk

Clearside Biomedical, Inc. Rakipler

Ikena Oncology

NasdaqGM:IKNA

US$83.5m

NGM Biopharmaceuticals

NasdaqGS:NGM

US$128.5m

Verrica Pharmaceuticals

NasdaqGM:VRCA

US$61.9m

Qilian International Holding Group

NasdaqCM:BGM

US$57.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Clearside Biomedical
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.34
52 Haftanın En Yüksek Seviyesi	US$2.12
52 Haftanın En Düşük Seviyesi	US$0.65
Beta	2.35
11 Aylık Değişim	32.67%
3 Aylık Değişim	5.51%
1 Yıllık Değişim	57.80%
33 Yıllık Değişim	-73.62%
5 Yıllık Değişim	78.67%
Halka arzdan bu yana değişim	-81.52%

Son Haberler & Güncellemeler

Recent updates

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 06

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Jun 24

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 12

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Aug 11

Clearside Biomedical Q2 2022 Earnings Preview

Aug 08

Clearside Biomedical: A Pivotal 2022 Ahead

Apr 13

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Dec 22

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Sep 30

Clearside's Value Proposition Is Far From Clear

Aug 07

We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Jun 17

Clearside Biomedical climbs after positive results from early-stage wet AMD trial

Jun 15

Clearside Biomedical resubmits eye treatment XIPERE NDA

May 03

If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Feb 16

Hissedar Getirileri

	CLSD	US Pharmaceuticals	US Pazar
7D	17.0%	-1.9%	-0.4%
1Y	57.8%	23.1%	34.1%

Getiri vs. Endüstri: CLSD exceeded the US Pharmaceuticals industry which returned 21.6% over the past year.

Getiri vs Piyasa: CLSD exceeded the US Market which returned 33.4% over the past year.

Fiyat Oynaklığı

Is CLSD's price volatile compared to industry and market?
CLSD volatility
CLSD Average Weekly Movement	9.0%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: CLSD hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: CLSD's weekly volatility (9%) has been stable over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2011	30	George Lasezkay	clearsidebio.com

Bir biyofarmasötik şirketi olan Clearside Biomedical, Inc. tedavilerin suprakoroidal boşluk yoluyla gözün arkasına iletilmesinde devrim yaratmaya odaklanmaktadır. Üveit maküler ödem tedavisi için triamsinolon asetonid suprakoroidal enjekte edilebilir süspansiyon olan XIPERE'i sunmaktadır. Ayrıca, yaş tip YBMD tedavisi için Faz IIb klinik çalışmasında olan suprakoroidal enjeksiyon için aksitinib enjekte edilebilir bir süspansiyon olan CLS-AX'ı geliştirmektedir.

Clearside Biomedical, Inc. Temel Bilgiler Özeti

Clearside Biomedical'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CLSD temel i̇stati̇sti̇kler
Piyasa değeri	US$94.93m
Kazançlar(TTM)	-US$33.46m
Gelir(TTM)	US$7.52m

13.3x

P/S Oranı

-3.0x

F/K Oranı

CLSD aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CLSD gelir tablosu (TTM)
Gelir	US$7.52m
Gelir Maliyeti	US$142.00k
Brüt Kâr	US$7.38m
Diğer Giderler	US$40.84m
Kazançlar	-US$33.46m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.45
Brüt Marj	98.11%
Net Kâr Marjı	-444.66%
Borç/Özkaynak Oranı	-165.2%

CLSD uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

CLSD Stoklara Genel Bakış

Ödüller

Risk Analizi

Clearside Biomedical, Inc. Rakipler

NasdaqGM:IKNA

US$83.5m

NasdaqGS:NGM

US$128.5m

NasdaqGM:VRCA

US$61.9m

NasdaqCM:BGM

US$57.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of Arcatus for Suprachoroidal Use in Uveitic Macular Edema Patients in China

Clearside Biomedical, Inc. Appoints Dr. Glenn Yiu to Its Scientific Advisory Board

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Clearside Biomedical, Inc. to Report Q1, 2024 Results on May 09, 2024

Recent updates

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of Arcatus for Suprachoroidal Use in Uveitic Macular Edema Patients in China

Clearside Biomedical, Inc. Appoints Dr. Glenn Yiu to Its Scientific Advisory Board

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Clearside Biomedical, Inc. to Report Q1, 2024 Results on May 09, 2024

Clearside Biomedical, Inc., Annual General Meeting, Jun 20, 2024

Insider recently bought US$130k worth of stock

Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors

New minor risk - Market cap size

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Clearside Biomedical, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering.

Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Consensus revenue estimates increase by 464%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Clearside Biomedical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 362%

New major risk - Revenue and earnings growth

New major risk - Negative shareholders equity

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clearside Biomedical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation At the American Society of Retina Specialists 41st Annual Scientific Meeting

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of Its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Clearside Biomedical, Inc. Opens Enrollment in Odyssey Phase 2B Clinical Trial of Cls-Ax (Axitinib Injectable Suspension) in Wet AMD

Consensus revenue estimates decrease by 57%

Consensus revenue estimates increase by 100%, EPS downgraded

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Medical Advisor-Retina notifies of intention to sell stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 9.4% to US$5.80

Clearside Biomedical, Inc. Executive Changes, Effective February 17, 2023

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

High number of new directors

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Price target increased to US$7.50

Clearside Biomedical, Inc. Announces Positive Results in Safety, Durability and Biologic Effect in Oasis Phase 1/2A Clinical Trial of Suprachoroidal CLS-AX (axitinib Injectable Suspension) in Wet AMD Patients

Clearside Biomedical, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical Q2 2022 Earnings Preview

Clearside Biomedical, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Clearside Biomedical Completes Dosing in Oasis Phase 1/2A Clinical Trial of CLS-AX in Wet AMD Patients

Clearside Biomedical, Inc. Appoints Susan Coultas as Chief Clinical Officer

Price target decreased to US$9.00

Consensus revenue estimates fall by 91%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Clearside Biomedical, Inc., Annual General Meeting, Jun 22, 2022

High number of new directors

Clearside Biomedical: A Pivotal 2022 Ahead

Bausch + Lomb and Clearside Biomedical, Inc. Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis